Barr Sees Rapid Uptake Of Allegra Generic, Downplays Impact From Competition
This article was originally published in The Pink Sheet Daily
Executive Summary
Barr/Teva's "at risk" generic of Sanofi-Aventis' fexofenadine antihistamine captures a 70% substitution rate with some large retailers in the first week after launch.
You may also be interested in...
Sanofi Seeks Injunction Against Teva/Barr Allegra Generic
A Newark, N.J. federal judge has scheduled an Oct. 24 hearing on Sanofi’s request for a preliminary injunction or expedited trial in the underlying patent dispute.
Sanofi Seeks Injunction Against Teva/Barr Allegra Generic
A Newark, N.J. federal judge has scheduled an Oct. 24 hearing on Sanofi’s request for a preliminary injunction or expedited trial in the underlying patent dispute.
Prasco To Launch Allegra “Authorized” Generic
Licensed version of Sanofi-Aventis’ antihistamine will begin shipping more than two weeks after Teva’s fexofenadine generic launched “at risk.”